Biolife Sciences (Biolife Sciences) Cash-to-Debt : 0.01 (As of May. 2008)

View and export this data going back to 2005. Start your Free Trial

What is Biolife Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Biolife Sciences's cash to debt ratio for the quarter that ended in May. 2008 was 0.01.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Biolife Sciences couldn't pay off its debt using the cash in hand for the quarter that ended in May. 2008.

The historical rank and industry rank for Biolife Sciences's Cash-to-Debt or its related term are showing as below:

BLFE's Cash-to-Debt is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 1.88
* Ranked among companies with meaningful Cash-to-Debt only.

Biolife Sciences Cash-to-Debt Historical Data

The historical data trend for Biolife Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Biolife Sciences Cash-to-Debt Chart

Biolife Sciences Annual Data

Trend

Nov04

Nov05

Nov06

Nov07

Cash-to-Debt

5.06

1.00

0.06

0.15

Biolife Sciences Quarterly Data
	Nov04	Feb05	May05	Aug05	Nov05	Feb06	May06	Aug06	Nov06	Feb07	May07	Aug07	Nov07	Feb08	May08
Cash-to-Debt	Get a 7-Day Free Trial										0.05	0.04	0.15	0.01	0.01

Competitive Comparison of Biolife Sciences's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, Biolife Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biolife Sciences's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolife Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Biolife Sciences's Cash-to-Debt falls into.

Biolife Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Biolife Sciences's Cash to Debt Ratio for the fiscal year that ended in Nov. 2007 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.409	/	(2.454	+	0.206)
	=	0.15

Biolife Sciences's Cash to Debt Ratio for the quarter that ended in May. 2008 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.04	/	(2.437	+	0.421)
	=	0.01

Biolife Sciences (OTCPK:BLFE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Biolife Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Biolife Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biolife Sciences (Biolife Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolife Sciences Inc (OTCPK:BLFE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

2831 Street Rose Parkway, No. 200, Henderson, NV, USA, 89052

Website

https://www.biolifesciences.com

Biolife Sciences Inc is a commercialization accelerator, licensor and developer of innovative and disruptive technologies for the healthcare, beauty and food and beverage industry sectors. The company's technologies include antimicrobial copper air filters and copper-infused textiles. Its revenues are primarily generated from the sale of sanitation products.

Executives

Arthur Viola

director, 10 percent owner, officer: CEO

Biolife Sciences (Biolife Sciences) Headlines

From GuruFocus

Rhino Novi Announces Name Change and New CEO

By Marketwired Marketwired • 09-15-2020